Skip to main content
DrugPrice

Farxiga vs Jardiance

Side-by-side cost comparison based on Medicare Part D data

Jardiance costs 21% less per claim than Farxiga ($210.00 vs $266.00). A generic version of Jardiance is also available, which may reduce costs further.

Cost Per Claim

Farxiga$266.00
Jardiance$210.00

Medicare Spending

Farxiga$3.0B
Jardiance$3.9B

Beneficiaries

Farxiga1,340,000
Jardiance2,150,000

Annual Cost Per Patient

Farxiga$2,229.00
Jardiance$1,835.00

Full Comparison

MetricFarxigaJardiance
Avg Cost Per Claim$266.00$210.00
Total Medicare Spending$3.0B$3.9B
Total Beneficiaries1,340,0002,150,000
Total Claims11,240,00018,760,000
Annual Cost/Patient$2,229.00$1,835.00
Year-over-Year Change+31.5%+22.7%
Generic AvailableYesYes
Patent ExpirationNov 13, 2025May 23, 2025
ManufacturerAstraZenecaBoehringer Ingelheim
ConditionDiabetesDiabetes
Generic NameDapagliflozinEmpagliflozin

Farxiga vs Jardiance: What the Data Shows

Farxiga (Dapagliflozin) and Jardiance (Empagliflozin) are both used to treat diabetes. Based on Medicare Part D data, Jardiance costs $210.00 per claim, which is 21% less than Farxiga at $266.00 per claim.

Medicare spent $3.0B on Farxiga and $3.9B on Jardiance. In terms of patient reach, Jardiance serves more beneficiaries (2,150,000 vs 1,340,000).

Year-over-year spending changed +31.5% for Farxiga and +22.7% for Jardiance. Farxiga saw significant spending growth, suggesting increased utilization or price increases. Jardiance saw significant spending growth, suggesting increased utilization or price increases.

Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.

Frequently Asked Questions

Jardiance is cheaper at $210.00 per claim, compared to $266.00 for Farxiga. That makes Jardiance about 21% less expensive per claim based on Medicare Part D data.

Yes, both Farxiga and Jardiance are used to treat diabetes. Your doctor can help determine which medication is more appropriate for your specific situation.

Both drugs have generic versions available. Generic Dapagliflozin and generic Empagliflozin can offer significant cost savings — typically 80-95% less than the brand name.

Medicare Part D spent $3.0B on Farxiga covering 1,340,000 beneficiaries, and $3.9B on Jardiance covering 2,150,000 beneficiaries.

Explore Further

Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.